EC0652 is a PSMA imaging agent with SPECT imaging capability. EC0652 can be used for the research of metastatic castration-resistant prostate cancer [1].
In Vitro, EC0652 demonstrates increased sensitivity for detecting bone lesions in metastatic castration-resistant prostate cancer compared with standard CT/bone scans[1].
References:
[1]. Zaidi S, et al. Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA Targeted Tubulysin Conjugate EC1169. Clin Cancer Res. Published online January 27, 2026.
In Vitro, EC0652 demonstrates increased sensitivity for detecting bone lesions in metastatic castration-resistant prostate cancer compared with standard CT/bone scans[1].
References:
[1]. Zaidi S, et al. Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA Targeted Tubulysin Conjugate EC1169. Clin Cancer Res. Published online January 27, 2026.
















